Results

Total Results: 4,731 records

Showing results for "secondary".

3061. Breast-Cancer-Medications Surveillance (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/breast-cancer-medications_surveillance.pdf
      July 01, 2012 - What is the evidence that harms or secondary potential benefits listed above affect treatment choice, … What is the evidence that harms or secondary potential benefits listed above affect treatment choice, … What is the evidence that harms or secondary potential benefits listed above affect treatment choice,

3062. Final Progress Report: Ambulatory Pediatric Patient Safety Learning Lab: Pursuing Safe Healthcare at Home (pdf file)
      www.ahrq.gov/sites/default/files/2025-03/walsh-kirkendall-report.pdf
      January 01, 2025 - A secondary outcome was the availability of key diabetes management supplies in the home setting. … Secondary Outcomes – real-world assessments accompanying simulation scenarios Participants were asked … from FMEAs and Process Mapping Other Design Outputs - Interventions T1D Simulation Study Results Secondary

3063. Disposition of Comments for CER 183 Tonsillectomy for OSDB (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/related_files/tonsillectomy-disposition-170415.pdf
      January 17, 2017 - of precision (e.g., confidence intervals), (d) dealt with PTH separately for primary hemorrhage, secondary … , line 10: States that tonsillectomy is "the most common surgery performed in the US" and cites a secondary … together under the single heading of PTH there were separate data for (a) primary hemorrhage, (b) secondary

3064. Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/hhrqMCEgbsBMJ_Ppbcp4yJ
      January 14, 2025 - It does not ap- ply to persons with secondary osteoporosis due to an underlying medical condition (eg … They do not apply to persons with secondary osteoporosis due to an underlying medical condition (eg, … Previous fracture Parental hip fracture Current smoking Glucocorticoid use Rheumatoid arthritis Secondary

3065. Microsoft Word - 2009-02.doc (pdf file)
      hcup-us.ahrq.gov/reports/methods/2009_02.pdf
      January 01, 2009 - Elements for Exclusions: Three data elements required for certain QIs were not available in every State: “secondary … data elements are used to exclude specific cases from the QI measures: • The PSIs and PDIs that use secondary … deliveries with no exclusions Patient Safety Indicators PSI 1 Complications of anesthesia in any secondary

3066. Archived: Evidence Summary: NSAIDs: Aspirin/NSAIDs for Prevention of Colorectal Cancer: Preventive Medication | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary-nsaids/aspirin-nsaids-for-prevention-of-colorectal-cancer-preventive-medication-2007
      March 15, 2007 - familial adenomatous polyposis or hereditary nonpolyposis colon cancer syndromes (Lynch I or II) and secondary … and subsequently subcategorized studies based on measures of dose effect, duration of exposure, and secondary … , 200 mg BID; Celecoxib, 400 mg BID Primary end point: adenoma at colonoscopy Secondary … Rofecoxib, 25 mg/d Primary end point: ≥1 adenoma at year 1 or 3 on colonoscopy Secondary

3067. Archived: Evidence Summary: Osteoporosis to Prevent Fractures: Screening | United States Preventive Services Taskforce
      www.uspreventiveservicestaskforce.org/uspstf/document/evidence-summary1/osteoporosis-screening-june-2018
      June 26, 2018 - The trial found evidence of benefit for a secondary outcome only, the incidence of hip fractures (low … fracture, parental hip fracture, current smoking, glucocorticoid steroid use, rheumatoid arthritis, secondary … None 1 47 (n = 62,492) 0.53 (0.53-0.54) FRISC 68 Age, weight, menopausal status, secondary … prior fracture, parental fracture, smoking, alcohol use, glucocorticosteroid use, rheumatoid arthritis, secondary

3068. Ch 6-User-Guide-To-Ocer 130129 (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/ch_6-user-guide-to-ocer_130129.pdf
      October 30, 2012 - validity as being of primary interest in assessing a PRO, with other measurement properties being secondary … measurement for an observational CER protocol Guidance Key Considerations Check Propose primary and secondary … – Followup period should be sufficient to observe hypothesized effects of treatment on primary and secondary

3069. Methods-Guide-Chapter-Prioritization-And-Selection-Of-Harms-For-Inclusion-In-Systematic-Reviews (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/prioritization-selection-of-harms.pdf
      February 01, 2018 - Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study … • If trials classified an adverse advent as primary or secondary outcomes, somebody has essentially … concomitant lip-tie Surgery Excessive bleeding; airway obstruction; pain; transient poor feeding secondary

3070. Managing Personal Health Information: An Action Agenda (pdf file)
      digital.ahrq.gov/sites/default/files/docs/citation/AHRQ_Personal_Health_InfoFinalReport_FINAL508compliant.pdf
      March 01, 2010 - A secondary Medical Expenditure Panel Survey-Household Component (MEPS-HC) analysis to identify variables … “Personal Health Information Management and the Design of Consumer Health Information Technology: Secondary … The secondary Medical Expenditure Panel Survey-Household Component (MEPS-HC) analysis conducted under … Personal Health Information and the Design of Consumer Health Information Technology: Secondary Analysis

3071. EPC Methods: An Exploration of Methods and Context for the Production of Rapid Reviews (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/pdf/rapid-review-production_white-paper.pdf
      February 01, 2015 - secondary sources varied: three products reported including systematic reviews and HTAs and one product … rapid response products apply a best evidence approach and report the results of primary studies if no secondary … Health: Clinical Evidence.”19 This product presents a list of the publications available, organized by secondary … Three preferentially looked for existing systematic reviews or HTAs, one never included secondary studies … • Reliance on secondary sources: Many organizations relied on existing systematic reviews or HTA reports

3072. Introduction to the NIS (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2022.pdf
      November 01, 2024 - and data elements that are not uniformly available across States, such as AHA hospital identifiers, secondary … data elements that were not available uniformly across the States, such as hospital identifiers, secondary … procedure information ICD-10-CM diagnoses I10_DX1 – I10_DX40 ICD-10-CM diagnoses, principal and secondary … Name Coding Notes ICD-10-PCS procedures I10_PR1 – I10_PR25 ICD-10-PCS procedures, principal and secondary … of days from admission to principal procedure PRDAY2 – PRDAY25 Number of days from admission to secondary

3073. HEALTHCARE COST AND UTILIZATION PROJECT — HCUP (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/NISIntroduction2019.pdf
      September 01, 2021 - and data elements that are not uniformly available across States, such as AHA hospital identifiers, secondary … data elements that were not available uniformly across the States, such as hospital identifiers, secondary … procedure information ICD-10-CM diagnoses I10_DX1 – I10_DX40 ICD-10-CM diagnoses, principal and secondary … Coding Notes ICD-10-PCS procedures I10_PR1 – I10_PR25 ICD-10-PCS procedures, principal and secondary … of days from admission to principal procedure PRDAY2 – PRDAY25 Number of days from admission to secondary

3074. Treatment of Osteoarthritis of the Knee: An Update Review (pdf file)
      effectivehealthcare.ahrq.gov/sites/default/files/osteoarthritis-knee-update-executive-170505.pdf
      May 01, 2017 - primary OA of the knee is the result of the progressive joint cartilage destruction over time, whereas secondary … chondroitin, and arthroscopic surgery (the title of the original review, “Treatment of Primary and Secondary … Treatment of primary and secondary osteoarthritis of the knee. … Physical Therapy Interventions for Knee Pain Secondary to Osteoarthritis. … Physical Therapy Interventions for Knee Pain Secondary to Osteoarthritis.

3075. Maskedstats Nis 2015Q1Q3 Dx Pr Grps (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/MaskedStats_NIS_2015Q1Q3_Dx_Pr_Grps.PDF
      November 08, 2017 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 237 0.00% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 2,123 0.04% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 13,751 … Distribution for DRG_NOPOA DRG_NoPOA Frequency Percent of Total 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … 0.11% 40: Multiple myeloma 2,715 0.05% 41: Cancer; other and unspecified primary 1,151 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

3076. Statins for Prevention of Cardiovascular Disease in Adults: Evidence Report and Systematic Review for the US Preventive Services Task Force (pdf file)
      www.uspreventiveservicestaskforce.org/home/getfilebytoken/mk-eb9VtB_jx885wnjuzk3
      January 01, 2024 - placebo or no statin on health outcomes in adults without prior CVD events (full list of primary and secondary … consistent with those from recent systematic reviews, some of which also included trials of statins for secondary … prevention.47,51-53 Similar to other meta-analyses of primary and secondary prevention trials,54,55 … cataracts (OR, 0.81 [95% CI, 0.71 to 0.93]).59 In contrast with systematic reviews of primary and secondary … Other analy- ses that included secondary prevention trials also suggested an as- sociation between higher

3077. Nis 2013 Maskedstats Core Weighted (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2013_MaskedStats_Core_Weighted.PDF
      January 01, 2013 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 1,905 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 11,425 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 98,005 … 0.28% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 6,765 0.02% please … 0.11% 40: Multiple myeloma 18,040 0.05% 41: Cancer; other and unspecified primary 7,230 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

3078. Nis 2012 Maskedstats Core (pdf file)
      hcup-us.ahrq.gov/db/nation/nis/tools/stats/NIS_2012_MaskedStats_Core.PDF
      January 01, 2012 - W OTHER O.R.PROC 1,126 0.02% 409: RADIOTHERAPY 566 0.01% 410: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … CC 26,601 0.36% 464: SIGNS & SYMPTOMS W/O CC 6,766 0.09% 465: AFTERCARE W HISTORY OF MALIGNANCY AS SECONDARY … DIAGNOSIS 148 0.00% 466: AFTERCARE W/O HISTORY OF MALIGNANCY AS SECONDARY DIAGNOSIS 1,743 0.02% 467 … 0.11% 40: Multiple myeloma 3,687 0.05% 41: Cancer; other and unspecified primary 1,480 0.02% 42: Secondary … disease) 14,189 0.19% 98: Essential hypertension 12,992 0.18% 99: Hypertension with complications and secondary

3079. Nrd 2012 Maskedstats Core V2 Weighted (pdf file)
      hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2012_MaskedStats_Core_V2_Weighted.PDF
      January 01, 2012 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 2,236 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 9,808 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 99,474 … 0.27% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 7,617 0.02% 849: RADIOTHERAPY … 0.11% 40: Multiple myeloma 19,996 0.05% 41: Cancer; other and unspecified primary 7,786 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary

3080. Nrd 2013 Maskedstats Core Weighted (pdf file)
      hcup-us.ahrq.gov/db/nation/nrd/stats/NRD_2013_MaskedStats_Core_Weighted.PDF
      January 01, 2013 - MYELOPROLIF DIS OR POORLY DIFF NEOPL DIAG W/O CC/MCC 1,941 0.01% 846: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY … DIAGNOSIS W MCC 11,070 0.03% 847: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W CC 98,666 … 0.28% 848: CHEMOTHERAPY W/O ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS W/O CC/MCC 6,678 0.02% please … 0.11% 40: Multiple myeloma 19,485 0.05% 41: Cancer; other and unspecified primary 7,609 0.02% 42: Secondary … Distribution for DXCCS1 DXCCS1 Frequency Percent of Total 99: Hypertension with complications and secondary